Clinical trial NCT06900608: Targeted ACT Compared to Supportive Therapy for Depression RCT
Official title: Targeted Acceptance and Commitment Therapy Compared to Supportive Therapy for Depressive Symptoms: a Pilot Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acceptance and Commitment Therapy
Supportive Therapy
Lead sponsor: Western Michigan University
Sponsor class: OTHER
First posted: 2025-03-28
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Acceptance and Commitment Therapy (ACT) has demonstrated efficacy in reducing depressive symptoms, primarily compared to no treatment or minimal treatment controls. This study compared the efficacy of ACT targeting cognitive defusion (CD, 3 sessions) and values-based activity scheduling (VBAS, 3 sessions) to supportive therapy (ST). Both treatments offered six sessions, a rationale for the approach, related techniques, and homework assignments. A parallel group randomized controlled efficacy trial design was used. Participants were stratified by gender identification and depression severity and then randomly allocated, according to a predetermined sequence, 2:1 to ACT or ST. Dependent measures were collected during acute treatment (pre, mid, and post-treatment) and follow-up at one-month.


Eligibility criteria: Inclusion Criteria:

* 18 years or older
* Scored one SD below the mean on the RSES and BSI
* Proficiency in English
* If taking medication for psychiatric reasons, stable medication use for at least eight weeks prior to enrollment and agreement to no changes in dosing during study participation.

Exclusion Criteria:

* Receiving other forms of psychological treatment
* Meeting PDSQ Interview criteria for psychosis, panic disorder, substance use, or endorsement of significant suicidal ideation

Primary outcomes:
measure: Demographic Questionnaire
timeFrame: Pre-treatment
measure: Rosenberg Self-Esteem Scale
timeFrame: Pre-treatment, 3 weeks, 6 weeks/post-treatment, and 1 month after post-treatment
measure: Brief Symptom Inventory-Global Severity Index
timeFrame: Pre-treatment, 3 weeks, 6 weeks/post-treatment, and 1 month after post-treatment
measure: Psychiatric Diagnostic Screening Questionnaire (PDSQ)
timeFrame: Pre-treatment, 3 weeks, 6 weeks/post-treatment, and 1 month after post-treatment
measure: Beck Depression Inventory - II (BDI)
timeFrame: Pre-treatment, 3 weeks, 6 weeks/post-treatment, and 1 month after post-treatment
measure: Acceptance and Action Questionnaire - II (AAQ-II)
timeFrame: Pre-treatment, 3 weeks, 6 weeks/post-treatment, and 1 month after post-treatment
measure: Automatic Thoughts Questionnaire (ATQ)
timeFrame: Pre-treatment, 3 weeks, 6 weeks/post-treatment, and 1 month after post-treatment
measure: Environmental Reward Observation Scale (EROS)
timeFrame: Pre-treatment, 3 weeks, 6 weeks/post-treatment, and 1 month after post-treatment
measure: Valued Living Questionnaire (VLQ)
timeFrame: Pre-treatment, 3 weeks, 6 weeks/post-treatment, and 1 month after post-treatment
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: